Protocol for the Examination of Specimens From Patients With Carcinoma of the Esophagus

Version: 4.2.0.1
Protocol Posting Date: June 2022
CAP Laboratory Accreditation Program Protocol Required Use Date: March 2022
The changes included in this current protocol version do not affect the prior accreditation date.

For accreditation purposes, this protocol should be used for the following procedures and tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Resection</td>
<td>Includes specimens designated esophagectomy and esophagogastrectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epithelial tumors of the esophagus</td>
<td>Includes all carcinomas and well-differentiated neuroendocrine tumors</td>
</tr>
<tr>
<td>Epithelial tumors of the esophagogastric junction</td>
<td>Includes tumors involving the esophagogastric junction with center no more than 2 cm into the proximal stomach</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td></td>
</tr>
<tr>
<td>Excisional biopsy (includes endoscopic resection and polypectomy)</td>
<td></td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)</td>
<td></td>
</tr>
<tr>
<td>Recurrent tumor</td>
<td></td>
</tr>
<tr>
<td>Cytologic specimens</td>
<td></td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor involving the esophagogastric junction (EGJ) with the tumor midpoint more than 2 cm into the proximal stomach (consider the Stomach Carcinoma protocol, see notes in relationship to EGJ)</td>
<td></td>
</tr>
<tr>
<td>Tumor midpoint is less than 2 cm into the proximal stomach, but the tumor does not involve the EGJ (consider the Stomach Carcinoma protocol)</td>
<td></td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocol)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor (GIST) (consider the GIST protocol)</td>
<td></td>
</tr>
<tr>
<td>Non-GIST sarcoma (consider the Soft Tissue protocol)</td>
<td></td>
</tr>
</tbody>
</table>

Authors
Lawrence J. Burgart, MD*; William V. Chopp, MD*; Dhanpat Jain, MD*.
With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- **Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.**
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.
Summary of Changes
v 4.2.0.1

- Update to Explanatory Note B
CASE SUMMARY: (ESOPHAGUS)
Standard(s): AJCC-UICC 8

SPECIMEN (Note A)

Procedure
___ Endoscopic resection
___ Esophagectomy
___ Esophagogastrectomy
___ Other (specify): ____________________
___ Not specified

TUMOR

Tumor Site (Note B) (select all that apply)
___ Cervical (proximal) esophagus: _________________
___ Mid esophagus, upper thoracic esophagus: _________________
___ Mid esophagus, middle thoracic esophagus: _________________
___ Mid esophagus, not otherwise specified: _________________
___ Distal esophagus (low thoracic esophagus): _________________
___ Esophagogastric junction (EGJ): _________________
___ Proximal stomach / cardia: _________________
___ Other (specify): _________________
___ Esophagus, not otherwise specified: _________________

Relationship of Tumor to Esophagogastric Junction (Note B)
___ Tumor is entirely located within the tubular esophagus and does not involve the esophagogastric junction
___ Tumor midpoint lies in the distal esophagus AND tumor involves the esophagogastric junction
___ Tumor midpoint is located at the esophagogastric junction#
# Use the stomach checklist if either (1) the tumor involves the EGJ, but the midpoint is more than 2 cm into the proximal stomach or (2) the midpoint is less than 2 cm into the proximal stomach, but the tumor does not involve the EGJ
___ Tumor midpoint is 2 cm or less into the proximal stomach or cardia and tumor involves the esophagogastric junction#
___ Not specified
___ Cannot be determined: _________________

Distance of Tumor Center from Esophagogastric Junction
___ Specify in Centimeters (cm): _________________ cm
___ Other (specify): _________________
___ Cannot be determined: _________________
___ Not applicable
Histologic Type (Note C)
___ Adenocarcinoma
___ Adenoid cystic carcinoma
___ Mucoepidermoid carcinoma
___ Adenosquamous carcinoma
___ Squamous cell carcinoma
___ Basaloid squamous cell carcinoma
___ Spindle cell squamous cell carcinoma
___ Verrucous squamous cell carcinoma
___ Undifferentiated carcinoma
___ Lymphoepithelioma-like carcinoma
___ Large cell neuroendocrine carcinoma
___ Small cell neuroendocrine carcinoma
# Select this option only if large cell or small cell cannot be determined.
___ Neuroendocrine carcinoma (poorly differentiated)#
___ Mixed squamous cell carcinoma-neuroendocrine carcinoma
___ Mixed adenocarcinoma-neuroendocrine carcinoma
___ Mixed adenocarcinoma-neuroendocrine tumor
___ G1, well-differentiated neuroendocrine tumor
___ G2, well-differentiated neuroendocrine tumor
___ G3, well-differentiated neuroendocrine tumor
___ Other histologic type not listed (specify): _________________
___ Carcinoma, type cannot be determined: _________________
+Histologic Type Comment: _________________

Histologic Grade# (Note D)
# This histologic grade is not applicable to adenoid cystic carcinoma, mucoepidermoid carcinoma, well-differentiated neuroendocrine tumor and high-grade neuroendocrine carcinoma.
___ G1, well differentiated
___ G2, moderately differentiated
___ G3, poorly differentiated, undifferentiated
___ Other (specify): _________________
___ GX, cannot be assessed: _________________
___ Not applicable

Tumor Size
___ Greatest dimension in Centimeters (cm): _________________ cm
+Additional Dimension in Centimeters (cm): ____ x ____ cm
___ Cannot be determined (explain): _________________

Tumor Extent (Note E)
___ High-grade dysplasia / carcinoma in situ (defined as malignant cells confined to the epithelium by the basement membrane)
___ Invades lamina propria
___ Invades muscularis mucosae
___ Invades submucosa
___ Invades muscularis propria
___ Invades adventitia
___ Invades adjacent structure(s) or organ(s)
   ___ Pleura: ____________________
   ___ Pericardium: ____________________
   ___ Azygos vein: ____________________
   ___ Diaphragm: ____________________
   ___ Peritoneum: ____________________
   ___ Aorta: ____________________
   ___ Vertebral body: ____________________
   ___ Airway: ____________________
   ___ Other (specify): ____________________
   ___ Cannot be determined: ____________________
___ No evidence of primary tumor

**Treatment Effect (Note F)**
___ No known presurgical therapy
___ Present, with no viable cancer cells (complete response, score 0)
___ Present, with single cells or rare small groups of cancer cells (near complete response, score 1)
___ Present, with residual cancer showing evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response, score 2)
___ Present (not otherwise specified)
___ Absent, with extensive residual cancer and no evident tumor regression (poor or no response, score 3)
___ Cannot be determined: ____________________

**Lymphovascular Invasion**
___ Not identified
___ Present
___ Cannot be determined: ____________________

**Perineural Invasion**
___ Not identified
___ Present
___ Cannot be determined: ____________________

**Tumor Comment:** ____________________

**MARGINS (Note G)**

**Margin Status for Invasive Carcinoma**
___ All margins negative for invasive carcinoma
___ Closest Margin(s) to Invasive Carcinoma (select all that apply)
   ___ Proximal: ____________________
   ___ Distal: ____________________
   ___ Radial: ____________________
   ___ Mucosal: ____________________
   ___ Deep: ____________________
   ___ Other (specify): ____________________
Cannot be determined: ________________________

Distance from Invasive Carcinoma to Closest Margin
Specify in Centimeters (cm)
___ Exact distance in cm: _________________ cm
___ Greater than 1 cm
Specify in Millimeters (mm)
___ Exact distance in mm: _________________ mm
___ Greater than 10 mm
Other
___ Other (specify): ________________________
___ Cannot be determined: ________________________
___ Invasive carcinoma present at margin

Margin(s) Involved by Invasive Carcinoma (select all that apply)
___ Proximal: ________________________
___ Distal: ________________________
___ Radial: ________________________
___ Mucosal: ________________________
___ Deep: ________________________
___ Other (specify): ________________________
___ Cannot be determined: ________________________
___ Other (specify): ________________________
___ Cannot be determined (explain): ________________________
___ Not applicable

Margin Status for Dysplasia and Intestinal Metaplasia (select all that apply)
___ All margins negative for dysplasia
___ Low-grade squamous dysplasia present at margin
Margin(s) Involved by Low-Grade Squamous Dysplasia (select all that apply)
___ Proximal: ________________________
___ Distal: ________________________
___ Mucosal: ________________________
___ Other (specify): ________________________
___ Cannot be determined: ________________________
___ High-grade squamous dysplasia present at margin
Margin(s) Involved by High-Grade Squamous Dysplasia (select all that apply)
___ Proximal: ________________________
___ Distal: ________________________
___ Mucosal: ________________________
___ Other (specify): ________________________
___ Cannot be determined: ________________________
___ Low-grade glandular dysplasia present at margin
Margin(s) Involved by Low-Grade Glandular Dysplasia (select all that apply)
___ Proximal: ________________________
___ Distal: ________________________
___ Mucosal: ________________________
___ Other (specify): ________________________
___ Cannot be determined: ________________________
___ High-grade glandular dysplasia present at margin
Margin(s) Involved by High-Grade Glandular Dysplasia (select all that apply)
___ Proximal: _________________
___ Distal: _________________
___ Mucosal: _________________
___ Other (specify): _________________
___ Cannot be determined: _________________
___ Intestinal metaplasia (Barrett esophagus) without dysplasia present at margin

Margin(s) Involved by Intestinal Metaplasia (select all that apply)
___ Proximal: _________________
___ Distal: _________________
___ Mucosal: _________________
___ Other (specify): _________________
___ Cannot be determined: _________________
___ Not applicable

+Margin Comment: _________________

REGIONAL LYMPH NODES

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
___ All regional lymph nodes negative for tumor
___ Tumor present in regional lymph node(s)

Number of Lymph Nodes with Tumor
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

Number of Lymph Nodes Examined
___ Exact number (specify): _________________
___ At least (specify): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________

+Regional Lymph Node Comment: _________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable (select all that apply)
___ Not applicable
___ Non-regional lymph node(s): _________________
___ Liver: _________________
___ Other (specify): _________________________________
___ Cannot be determined: _________________________________

PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition) (Note H)
Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician's responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

TNM Descriptors (select all that apply)
___ Not applicable: _________________________________
___ m (multiple primary tumors)
___ r (recurrent)
___ y (post-treatment)

pT Category
___ pT not assigned (cannot be determined based on available pathological information)
___ pT0: No evidence of primary tumor
___ pTis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane

\[ pT1: \text{tumor invades the lamina propria, muscularis mucosae, or submucosa} \]
___ pT1a: Tumor invades the lamina propria or muscularis mucosae
___ pT1b: Tumor invades the submucosa
___ pT1 (subcategory cannot be determined)
___ pT2: Tumor invades the muscularis propria
___ pT3: Tumor invades adventitia

\[ pT4: \text{tumor invades adjacent structures} \]
___ pT4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum
___ pT4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway
___ pT4 (subcategory cannot be determined)

pN Category (Note J)
___ pN not assigned (no nodes submitted or found)
___ pN not assigned (cannot be determined based on available pathological information)
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis in one or two regional lymph nodes
___ pN2: Metastasis in three to six regional lymph nodes
___ pN3: Metastasis in seven or more regional lymph nodes

pM Category (required only if confirmed pathologically)
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis

ADDITIONAL FINDINGS (Note J)

+Additional Findings (select all that apply)
___ None identified
___ Intestinal metaplasia (Barrett's esophagus)
___ Low-grade squamous dysplasia
___ High-grade squamous dysplasia
___ Low-grade glandular dysplasia
___ High-grade glandular dysplasia
___ Esophagitis (specify type): ____________________
___ Gastritis (specify type): ____________________
___ Other (specify): ____________________

SPECIAL STUDIES
For HER2 reporting, the CAP Gastric HER2 template should be used. Pending biomarker studies should be listed in the Comments section of this report.

COMMENTS

Comment(s): ____________________
Explanatory Notes

A. Application
This protocol applies to:
1) All carcinomas arising in the esophagus
2) Carcinomas involving the esophagogastric junction (EGJ), with tumor midpoint ≤2 cm into the proximal stomach/cardia
3) Well-differentiated neuroendocrine tumors, WHO grade 1, 2 and grade 3 (stage grouping for prognosis is not used) *

This protocol DOES NOT apply to:
1) Carcinomas involving the EGJ, with tumor midpoint >2 cm into the proximal stomach (use CAP protocol for gastric cancer)
2) Carcinomas of the cardia/proximal stomach without involvement of the EGJ even if tumor midpoint is ≤2 cm into the proximal stomach (use CAP protocol for gastric cancer)
3) Lymphomas, gastrointestinal stromal tumors, and sarcomas.

* Esophageal well-differentiated neuroendocrine tumors are so rare, a separate staging system is not warranted.

References

B. Location
The location of the tumor in the esophagus (cervical, upper thoracic, middle thoracic, lower thoracic, abdominal) and with respect to the macroscopic EGJ (defined as where the tubular esophagus meets the stomach, as measured from the top of the gastric folds) should be noted whenever possible (Figure 1). Cancers located in the cervical esophagus are staged as upper thoracic esophageal cancer. The abdominal esophagus is included in the lower thoracic esophagus. The macroscopic EGJ often does not correspond to the junction of esophageal squamous mucosa and columnar mucosa because of the common finding in esophageal resection specimens of glandular mucosa involving the distal esophagus. Because anatomic divisions of the esophagus are defined by anatomic boundaries and relationships to other structures, it may not be possible for the pathologist to determine exact tumor location from the resection specimen.
Figure 1. Anatomic subdivisions of the esophagus. From Amin et al.1 Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 8th edition (2017) published by Springer Science and Business Media LLC, www.springerlink.com.

For tumors involving the EGJ, specific observations should be recorded in an attempt to establish the exact site of origin of the tumor. The EGJ is defined as the junction of the tubular esophagus and the stomach, irrespective of the type of epithelial lining of the esophagus. The pathologist should record the maximum longitudinal dimension of the tumor mass (see Note E), the distance of the tumor midpoint from the EGJ, and the relative proportions of the tumor mass located in the esophagus and in the stomach.

Siewart classification divides adenocarcinomas involving the EGJ into 3 categories, based upon location of the midpoint of the tumor.2

Type I: Carcinoma of the distal esophagus, with or without infiltration of the EGJ from above
Type II: True carcinoma of the gastric cardia, arising from the cardiac epithelium or short segments with intestinal metaplasia at the EGJ
Type III: Subcardial gastric carcinoma, which infiltrates the EGJ and distal esophagus from below

In the AJCC 8th edition, tumors involving the EGJ that have a midpoint within the proximal 2 cm of the cardia/proximal stomach are to be staged as esophageal cancers. Cancers whose midpoint is more than 2 cm distal from the EGJ, even if EGJ is involved, should be staged using the stomach cancer TNM and stage groupings.1 Based on the AJCC 8th edition, all Siewart type I and some of Siewart type II tumors use the esophageal cancer TNM and stage groupings.

References
C. Histologic Type
For consistency in reporting, the histologic classification proposed by the WHO is recommended. However, this protocol does not preclude the use of other systems of classification or histologic types. This protocol includes esophageal well-differentiated neuroendocrine tumors due to the fact that well-differentiated neuroendocrine tumors are extremely rare in the esophagus.

Worldwide, squamous cell carcinoma continues to be predominant as the most common histologic type, but numerous population-based studies document the increasing incidence of adenocarcinoma of the esophagus and EGJ in Western countries. More than 50% of esophageal carcinomas diagnosed in the United States since 1900 are adenocarcinomas. Other subtypes, such as adenoid cystic carcinoma and mucoepidermoid carcinoma, which resemble their counterparts arising in salivary gland, are rarely encountered.

The TNM staging system for esophageal carcinomas incorporates tumor grade and histologic type in the stage groupings (see Note H). Mixed histologic types, such as adenosquamous carcinomas, are staged using the squamous cell carcinoma stage grouping.

References

D. Histologic Grade
The histologic grades for esophageal squamous cell carcinomas are as follows:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Grade cannot be assessed</td>
</tr>
<tr>
<td>1</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>2</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>3</td>
<td>Poorly differentiated, undifferentiated</td>
</tr>
</tbody>
</table>

If there are variations in the differentiation within the tumor, the highest (least favorable) grade is recorded. Every effort should be avoid signing out a histologic grade as “undifferentiated.” If this cannot be resolved, the cancer should be staged as a G3 squamous cell carcinoma.

For adenocarcinomas, a suggested grading system based on the proportion of the tumor that is composed of glands is as follows:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Grade cannot be assessed</td>
</tr>
<tr>
<td>1</td>
<td>Well-differentiated (greater than 95% of tumor composed of glands)</td>
</tr>
<tr>
<td>2</td>
<td>Moderately differentiated (50% to 95% of tumor composed of glands)</td>
</tr>
<tr>
<td>3</td>
<td>Poorly differentiated (49% or less of tumor composed of glands)</td>
</tr>
</tbody>
</table>
For purposes of staging, all undifferentiated carcinomas are staged as grade 3 squamous cell.\textsuperscript{1} Small cell and large cell neuroendocrine carcinomas are not typically graded but are high-grade tumors. In general, mucoepidermoid carcinoma and adenoid cystic carcinoma of the esophagus are not amenable to grading.

Well-differentiated neuroendocrine tumors (NETs) of the esophagus are extremely rare. The WHO classification of the digestive NETs can be used to grade the tumors.

References

\textbf{E. Tumor Extension}

For purposes of data reporting, Barrett’s esophagus with high-grade dysplasia in an esophageal resection specimen is reported as carcinoma in situ. The term carcinoma in situ is not widely applied to glandular neoplastic lesions in the gastrointestinal tract but is retained for tumor registry reporting purposes as specified by law in many states. Invasion of the lamina propria may be difficult to assess for glandular neoplasms in the esophagus. The muscularis mucosae (Figure 2) is commonly duplicated and thickened in Barrett’s esophagus; invasion of this layer should not be misinterpreted as invasion of the muscularis propria.\textsuperscript{1} It should be noted that the muscularis mucosae varies in organization from relatively sparse bundles of smooth muscle in the cervical esophagus to a thickened reticulated network in the distal esophagus.\textsuperscript{2}

\textbf{Figure 2.} Microscopic anatomy of the esophagus. From Amin et al.\textsuperscript{3} Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the \textit{AJCC Cancer Staging Manual}, 8th edition (2017) published by Springer Science and Business Media LLC, \url{www.springerlink.com}.

Lymphatic channels are present in the entire layer of the esophagus, including the lamina propria, but they are most concentrated in the submucosa. The longitudinal nature of the submucosal lymphatic plexus allows lymphatic spread orthogonal to depth of tumor invasion. Occasionally skip lesions are present in the resection specimens, possibly caused by longitudinal lymphatic spread. If there are multiple discrete lesions, the tumor length is measured from the top of the highest lesion to the bottom of the lowest.\textsuperscript{3} The suffix “m” is required in this instance (see Note H). Tumor length may be a strong predictor for the presence or absence of nodal disease in early to intermediate-stage esophageal cancer.
References

F. Treatment Effect
Response of tumor to previous chemotherapy or radiation therapy should be reported. Several systems for tumor response have been advocated, and a modified Ryan scheme is suggested, which has been shown to provide good interobserver reproducibility provide prognostic significance in rectal cancer.1

Modified Ryan Scheme for Tumor Regression Score1

<table>
<thead>
<tr>
<th>Description</th>
<th>Tumor Regression Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No viable cancer cells (complete response)</td>
<td>0</td>
</tr>
<tr>
<td>Single cells or rare small groups of cancer cells (near complete response)</td>
<td>1</td>
</tr>
<tr>
<td>Residual cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response)</td>
<td>2</td>
</tr>
<tr>
<td>Extensive residual cancer with no evident tumor regression (poor or no response)</td>
<td>3</td>
</tr>
</tbody>
</table>

Sizable pools of acellular mucin may be present after chemoradiation but should not be interpreted as representing residual tumor.

This protocol does not preclude the use of other systems for assessment of tumor response.2 3 4

References

G. Margins
Margins include the proximal, distal, and radial margins. The radial margin represents the adventitial soft tissue margin closest to the deepest penetration of tumor. Sections to evaluate the proximal and distal resections margins can be obtained in 2 orientations: (1) en face sections parallel to the margin or (2)
longitudinal sections perpendicular to the margin. Depending on the closeness of the tumor to the margin, select the orientation(s) that will most clearly demonstrate the status of the margin. The distance from the tumor edge to the closest resection margin(s) should be measured if all margins are uninvolved by invasive carcinoma. Proximal and distal resection margins should be evaluated for Barrett’s esophagus and for squamous and glandular dysplasia if they are not involved by invasive carcinoma. It may be helpful to mark the margin(s) closest to the tumor with ink. Margins marked by ink should be so designated in the macroscopic description.

H. TNM and Anatomic Stage/Prognostic Groupings
The TNM staging system for esophageal carcinoma of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended (Figure 3).1

![Figure 3. T, N, and M classifications for esophageal carcinoma. From Amin et al.] Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, 8th edition (2017) published by Springer Science and Business Media LLC, www.springerlink.com.

According to AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when
technically infeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**
For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. In the AJCC 8th edition, “y” affects the stage grouping.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or after initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor before multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

**N Category Considerations**
A mediastinal lymphadenectomy specimen will ordinarily include 7 or more regional lymph nodes. The minimum number of lymph nodes needed for adequate staging for esophageal cancers in esophagectomy or gastroesophagectomy specimens has not been determined. The periesophageal soft tissue should be dissected thoroughly to maximize the lymph node yields. In patients who receive preoperative treatment, lymph nodes may become fibrotic/atrophic. Lymph nodes with acellular mucin lakes are not considered as positive lymph nodes. Cytokeratin stains may aid identification of residual cancer cells in lymph nodes; however, they should be interpreted in conjunction with morphologic findings.

**Prognostic/Stage Groupings**
Different stage groupings are used for squamous cell carcinomas and adenocarcinomas. In addition, a separate stage grouping is used to stage patients receiving neoadjuvant treatment due to the fact that prognostic implication for ypTNM differs from those of equivalent pTNM.¹

Location plays a role in the stage grouping of esophageal squamous cell carcinomas:
<table>
<thead>
<tr>
<th>Location Category</th>
<th>Location Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Location Unknown</td>
</tr>
<tr>
<td>Upper</td>
<td>Cervical esophagus to lower border of azygos vein</td>
</tr>
<tr>
<td>Middle</td>
<td>Lower border of azygos vein to lower border of inferior pulmonary vein</td>
</tr>
<tr>
<td>Lower</td>
<td>Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction</td>
</tr>
</tbody>
</table>

*Note:* Location is defined by the position of the midpoint of the tumor in the esophagus.

**Additional Descriptors**

**Lymphovascular Invasion**

Lymphovascular invasion (LVI) indicates whether microscopic lymphovascular invasion is identified in the pathology report. LVI includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

**References**


**I. Regional Lymph Nodes**

Regional lymph nodes (Figure 4) extend from periesophageal cervical nodes for the cervical esophagus to celiac lymph nodes for the distal esophagus. Number of involved lymph nodes has consistently emerged as a prognostic indicator on multivariate analysis. Extranodal extension may identify a subset of node-positive patients with a particularly poor prognosis. Total number of lymph nodes containing metastases (positive nodes) is demonstrated to be an important prognostic factor for esophageal cancer. For that reason, lymph node involvement is coarsely grouped into N0 (no positive lymph node), N1 (1-2 positive lymph nodes), N2 (3-6 positive lymph nodes), and N3 (7 or more positive lymph nodes).

*Figure 4.* Regional lymph nodes of the esophagus. From Amin et al. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Manual, 8th edition* (2017) published by Springer Science and Business Media LLC, www.springerlink.com.
References


J. Additional Findings

Most esophageal adenocarcinomas develop in the setting of Barrett’s esophagus, which is defined as alteration of the mucosal lining of the esophagus from the normal squamous epithelium to metaplastic columnar epithelium in response to esophagogastric reflux. Although in some cases the columnar epithelium may resemble gastric oxyntic or cardiac mucosa, only the specialized columnar epithelium with goblet cells is considered to carry significant risk of cancer and is designated as Barrett’s esophagus for diagnostic purposes in the United States. However, controversy remains whether the definition should be limited to columnar epithelium with goblet cells or should be expanded to include non-goblet cell columnar epithelium.